-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Get Moving and Win During the 2024 Wellness Challenge
Stay active during your time in San Diego by taking part in IASLC’S Wellness Challenge, Step It Up for Research.
-
Know Before You Go: What You Need to Know to Get to—and Navigate—San Diego
With the 2024 World Conference on Lung Cancer less than a month away, now is the time to make sure you know where you’re headed and how to get there.
-
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population.
-
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2
In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative.
-
Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases
Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA.
-
Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC
Presenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need.
-
CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date
When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer.
-
Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC
Dr. Natasha Leighl said the findings of PALOMA-3 show subcutaneous dosing offers other advantages, including reduced adverse events.
-
KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC
Dr. Tony Mok said the results of the phase III KRYSTAL-12 trial reinforce adagrasib as an effective second-line treatment option for this patient population.
-
LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC
Primary results from the study, presented by Dr. Suresh Ramalingam, showed osimertinib offers a significant improvement in progression-free survival following chemoradiotherapy.